Fagomine (D-Fagomine) is a mild glycosidase inhibitor, an analog of 1-deoxynojirimycin (DNJ) with hypoglycemic activity, and Fagomine reduces intracellular reactive oxygen species (ROS) production and malondialdehyde (MDA) levels.

Ophiopogonin D(OPD) significantly inhibited the in vitro and in vivo growth of prostate cells via RIPK1 OPD may be developed as a potential anti-prostate cancer agent.

Zidesamtinib (NVL-520) is an orally active, selective, potent, and blood-brain-barrier-crossing inhibitor of ROS1 fusion and resistance mutations, inhibits ROS1 and ROS1 G2032R, and can be used in the study of non-small-cell lung cancer and solid tumors.